Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-12
2007-06-12
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C514S339000, C546S194000, C546S201000, C546S277400
Reexamination Certificate
active
10466969
ABSTRACT:
The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
REFERENCES:
patent: 5521196 (1996-05-01), Audia et al.
patent: 5521197 (1996-05-01), Audia
patent: 5708008 (1998-01-01), Audia et al.
patent: 5792763 (1998-08-01), Fritz et al.
patent: 5942536 (1999-08-01), Fritz et al.
patent: 6133287 (2000-10-01), Slassi et al.
patent: WO 00/63203 (2000-10-01), None
patent: WO 01/09088 (2001-02-01), None
Franz et al., “5-HT6 receptor antagonism potentiates, etc.,” Neuropharmacology 42 (2002) 170-180.
Glennon et al., “2-Substituted Tryptamines, etc.,” J. Med. Chem. 2000, 43, 1011-1018.
Rogers et al., “5-HT6 receptor antagonists enhance, etc.,” Psychopharmacology (2001) 158: 114-119.
Branchek et al., “5-HT6 receptors as emerging, etc.,” Annu. Rev. Pharmacol. Toxicol. 2000, 40: 319-34.
Barnes et al., “A review of central 5-HT, etc.,”Neuropharmacology, 38 (1999) 1083-1152.
Stephen L. Gwaltney, II, et al., “Novel sulfonate Analogues of Combretastatin A-4: Potent Antimitotic Agents,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 871-874 (2001).
Gwaltney et al., “Novel Sulfonate Analogues of Combretastatin A-4: Potent Antimitotic Agents,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 871-874 (2001).
Bos et al., “5-HT6 receptor antagonists: lead optimization and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides,”Eur. J. Med. Chem.., vol. 36, pp. 165-178 (2001).
Bourson et al., “Determination of the Role of the 5-HT6 Receptor in the Rat Brain: A Study using Antisense Iligonucleotides,”J. Pharm. And Experimental Therapeutics, vol. 274, No. 1, pp. 173-180(1995).
Branchek et al., “5-HT6 Receptors as Emerging Targets for Drug Discovery,”Annual Rev. of Pharmacology and Toxicology, vol. 40 pp. 319-334 (2000).
Dawson et al., et al., “In Vivo Effects of the 5-HT6 Antagonist SB-271046 on Striatal and Frontal Cortex Extracellular Concentrations of Noradrenaline, Dopamine, 5-HT, Glutamate and Aspartate,”British J. of Pharmacology, vol. 130, pp. 23-26 (2000).
Meneses, Alfredo, “Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation,”Behavioral Brain Research, vol. 118, pp. 107-110 (2001).
Ohmori et al., “Novel Polymorphism in the 5′-upstream Region of the Human 5-HT6 Receptor Gene and Schizophrenia,”Neuroscience Let., vol. 310, pp. 17-20 (2001).
Rogers et al., “5-HT6 receptor antagonists enhance retention of a water maze task in the rat,”Psyhopharmacology, vol. 158, pp. 114-119 (2001).
Tsai et al., “N1-(Benzenesulfonyl)tryptamines as Novel 5-HT6Antagonists,”Bioorganic&Med. Chem. Let., vol. 10, pp. 2295-2299 (2000).
Yoshioka et al.,“Central Distribution and Function of 5-HT6 Receptor Subtype in the Rat Brain,”Life Sciences, vol. 62, Nos. 17/18, pp. 1473-1477 (1998).
Filla Sandra Ann
Flaugh Michael Edward
Gillig James Ronald
Heinz Lawrence Joseph
Krushinski, Jr. Joseph Herman
Combs Tonya L.
Desai Manisha A.
Eli Lilly and Company
McGraw Elizabeth A.
Morris Patricia L.
LandOfFree
Benzenesulfonic acid indol-5-yl esters as antagonists of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzenesulfonic acid indol-5-yl esters as antagonists of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzenesulfonic acid indol-5-yl esters as antagonists of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3817271